Molecular Therapy-methods & Clinical Development SCIESCI

The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella.

Topics of particular interest within the journal's scope include:

Gene vector engineering and production,

Methods for targeted genome editing and engineering,

Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells,

Methods for gene and cell vector delivery,

Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine,

Analysis of gene and cell vector biodistribution and tracking,

Pharmacology/toxicology studies of new and next-generation vectors,

Methods for cell isolation, engineering, culture, expansion, and transplantation,

Cell processing, storage, and banking for therapeutic application,

Preclinical and QC/QA assay development,

Translational and clinical scale-up and Good Manufacturing procedures and process development,

Clinical protocol development,

Computational and bioinformatic methods for analysis, modeling, or visualization of biological data,

Negotiating the regulatory approval process and obtaining such approval for clinical trials.

《分子疗法—方法和临床开发》的目标是在分子疗法成功发表重要的同行评审方法和程序的基础上，以及分子疗法伞下广泛领域的转化进展。< /p>

期刊范围内特别感兴趣的主题包括：

基因载体工程和生产，

靶向基因组编辑和工程方法，

细胞重编程和多能细胞定向分化的方法和技术开发，

基因和细胞载体的传递方法，

开发用于基因和细胞治疗以及再生医学的生物材料和纳米粒子，

基因和细胞载体生物分布和追踪分析，

新型和下一代载体的药理学/毒理学研究，

细胞分离、工程化、培养、扩增和移植的方法，

用于治疗应用的细胞处理、存储和存储，

临床前和 QC/QA 分析开发，

转化和临床放大以及良好制造程序和工艺开发，

临床方案开发，

用于分析、建模或可视化生物数据的计算和生物信息学方法，

协商监管审批流程并获得此类临床试验批准。

该刊已被国际权威数据库SCIE、SCI收录，是国际顶级期刊。该刊致力于发表经过严格同行评审的高质量原创文章，反映Biochemistry, Genetics and Molecular Biology-Molecular Biology领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2022年影响因子为4.7，平均审稿速度为12 Weeks，近三年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。